Biotechnologically engineered protein binders for applications in amyloid diseases

Haupt, Christian; Fändrich, Marcus

doi:10.1016/j.tibtech.2014.08.004

Cited by 6 publications

(5 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apart from antibodies, several engineered binding proteins with specificities for different forms of the amyloid-β peptide have been generated during recent years [ 69 ]. These protein reagents appear useful for the detection, diagnosis or imaging of Aβ or amyloid deposits and could even offer potential as novel therapeutics for the treatment of AD.…”

Section: Discussionmentioning

confidence: 99%

High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide

Rauth

Hinz

Börger

et al. 2016

Biochemical Journal

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide

Rauth

Hinz

Börger

et al. 2016

Biochemical Journal

View full text Add to dashboard Cite

show abstract

“…The fragment peptides corresponding to the core regions themselves can adopt β‐strand conformation and form nanofibers resembling the nanofibers of the intact proteins. In addition, the amyloid core peptides have affinity with their parent proteins through sequence homology and can be used to prevent fibril formation of them. This is one of the important functions of amyloidogenic core peptides and enables the development of therapeutic compounds that prevent anomalous aggregation of proteins.…”

Section: Amyloidogenic Peptides For the Treatment Of Alzheimer's Disementioning

confidence: 99%

“…Copyright 2013 American Chemical Society.) (c) Schematic illustration of OVA nanoparticle formation by heating a mixture of OVA and guanidine‐terminated dendrimer bearing the IAIMSA from amyloidogenic core peptides of OVA. (Reprinted with permission from reference 58.…”

Section: Amyloidogenic Peptides For the Treatment Of Alzheimer's Disementioning

confidence: 99%

Recent advances in nanofibrous assemblies based on β‐sheet‐forming peptides for biomedical applications

Waku

Tanaka

2016

Polymer International

View full text Add to dashboard Cite

Amyloid fibrils are supramolecular polymers with -sheet-rich structures formed by polymerization of protein/peptide with intermolecular interaction. Amyloid fibrils have been miscast as toxic villains since they have historically been studied as pathogens associated with serious diseases, including Alzheimer's and Parkinson's disease. However, recent studies on their toxicity and formation mechanism and discovery of their functionality in nature correct the misconception and strongly facilitate the possible use of -sheet-forming peptides in designing novel nanomaterials. Self-assembly based on -sheet-forming peptides can provide highly ordered nanostructures under certain conditions. Therefore, ingenious design of the building block peptides allows the construction of nano-assemblies, which contain large quantities of bio-functional molecules, including drugs and bioactive peptides, and exhibit unique properties, such as assembly or disassembly in response to external stimulus or specific molecules. These properties provide a novel strategy for the creation of innovative nanomaterials, especially for biomedical applications. Here, we describe recent progress in the biomedical application of fibrous assemblies based on -sheet-forming peptides, such as the suppression of aberrant protein aggregation, controlled release, tissue engineering and other applications. This review focuses not only on the function of the nanofibrous assemblies but also on the functions of component molecules, namely amyloidogenic peptides.

show abstract

“…dendrimers possess internal nanostructures for entrapment of several therapeutic agents. The possibility of functionalizing the outer groups of dendrimers with ligands of interest used to study the physical interactions of these macromolecules with the Aβ peptide [1, [46][47][48][49][50][51][52] ( • ▶ Fig. 8).…”

Section: Dendrimersmentioning

confidence: 99%

An Update on Biomedical Application of Nanotechnology for Alzheimer’s Disease Diagnosis and Therapy

et al. 2016

View full text Add to dashboard Cite

Approximately 35 million people worldwide suffer from Alzheimer's disease (AD). The cellular uptake and specific transport of drugs and imaging agents to brain are common issues in the diagnosis and therapy of AD. New advances in nanotechnology have supplied favorable solutions to this issue. Various nanocarriers such as polymeric nanoparticles, liposomes, micelles, dendrimers and nanogels have been studied for the delivery of drugs and imaging agents to brain. This review presents a succinct discussion of the applications of nanotechnology for Alzheimer's disease diagnosis and therapy.

show abstract

Biotechnologically engineered protein binders for applications in amyloid diseases

Cited by 6 publications

References 77 publications

High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide

High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide

Recent advances in nanofibrous assemblies based on β‐sheet‐forming peptides for biomedical applications

An Update on Biomedical Application of Nanotechnology for Alzheimer’s Disease Diagnosis and Therapy

Contact Info

Product

Resources

About